TY  - JOUR
A1  - Ranki, Tuuli
A1  - Joensuu, Timo
A1  - Jäger, Elke
A1  - Karbach, Julia
A1  - Wahle, Claudia
A1  - Kairemo, Kalevi
A1  - Alanko, Tuomo
A1  - Partanen, Kaarina
A1  - Turkki, Riku
A1  - Linder, Nina
A1  - Lundin, Johan
A1  - Ristimäki, Ari
A1  - Kankainen, Matti
A1  - Hemminki, Akseli
A1  - Backman, Charlotta
A1  - Dienel, Kasper
A1  - Euler, Mikael von
A1  - Haavisto, Elina
A1  - Hakonen, Tiina
A1  - Juhila, Juuso
A1  - Jaderberg, Magnus
A1  - Priha, Petri
A1  - Vassilev, Lotta
A1  - Vuolanto, Antti
A1  - Pesonen, Sari
T1  - Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8C T-cell response, prominent infiltration of CD8C lymphocytes and Th1 type polarization
T2  - OncoImmunology
N2  - Late stage cancer is often associated with reduced immune recognition and a highly immunosuppressive tumor microenvironment. The presence of tumor infiltrating lymphocytes (TILs) and specific gene-signatures prior to treatment are linked to good prognosis, while the opposite is true for extensive immunosuppression. The use of adenoviruses as cancer vaccines is a form of active immunotherapy to initialise a tumor-specific immune response that targets the patient’s unique tumor antigen repertoire. We report a case of a 68-year-old male with asbestos-related malignant pleural mesothelioma who was treated in a Phase I study with a granulocyte-macrophage colony‑stimulating factor (GM-CSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in prominent infiltration of CD8C lymphocytes to tumor, marked induction of systemic antitumor CD8C T-cells and induction of Th1- type polarization in the tumor. These results indicate that ONCOS-102 treatment sensitizes tumors to other immunotherapies by inducing a T-cell positive phenotype to an initially T-cell negative tumor.
KW  - adenovirus
KW  - antitumor immunity
KW  - cytotoxic immunotherapy
KW  - GM-CSF
KW  - Th1 polarization
KW  - tumor infiltrating lymphocytes
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/40217
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-402176
VL  - 3
IS  - 10:e958937
PB  - Landes Bioscience
CY  - Austin, Tex
ER  -